DGIdb - OLANZAPINE Drug Record

OLANZAPINE chembl:CHEMBL715 Approved

Alternate Names:

ZYPREXA
OLANZAPINE
LY170053
LY-170053
ARKOLAMYL
ZYPREXA ZYDIS
ZALASTA
pubchem.compound:4585
OLANZAPINUM
OLANZAPINA
2-METHYL-4-(4-METHYL-1-PIPERAZINYL)-10H-THIENO[2,3-B][1,5]BENZODIAZEPINE
OLANZAPIN
drugbank:00334
chemidplus:132539-06-1
chembl:CHEMBL715
rxcui:61381

Drug Info:

Drug Indications	antidepressant,for treatment of bipolar disorder
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antipsychotic agent
Year of Approval	1996
Drug Class	antipsychotic agents
Drug Categories	adrenergic alpha-1 receptor antagonists
Drug Categories	adrenergic alpha-antagonists
Drug Categories	adrenergic antagonists
Drug Categories	agents producing tachycardia
Drug Categories	anticholinergic agents
Drug Categories	antidepressive agents
Drug Categories	cytochrome p-450 cyp2c19 inhibitors (weak)
Drug Categories	cytochrome p-450 cyp2c9 inhibitors (weak)
Drug Categories	cytochrome p-450 cyp2d6 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 cyp3a4 inhibitors
Drug Categories	cytochrome p-450 cyp3a4 inhibitors (weak)
Drug Categories	cytochrome p-450 enzyme inhibitors
Drug Categories	cytochrome p-450 substrates
Drug Categories	dopamine antagonists
Drug Categories	dopamine d2 receptor antagonists
Drug Categories	heterocyclic compounds, fused-ring
Drug Categories	histamine antagonists
Drug Categories	histamine h1 antagonists
Drug Categories	histamine h2 antagonists
Drug Categories	hypotensive agents
Drug Categories	muscarinic antagonists
Drug Categories	p-glycoprotein substrates
Drug Categories	potential qtc-prolonging agents
Drug Categories	qtc prolonging agents
Drug Categories	serotonergic drugs shown to increase risk of serotonin syndrome
Drug Categories	serotonin 5-ht2 receptor antagonists
Drug Categories	serotonin receptor antagonists
Drug Categories	ugt1a4 substrates

(5 More Sources)

Publications:

Arranz MJ et al., 1998, Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response., Pharmacogenetics
Eum S et al., 2017, Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report., BMC Psychiatry
Sukasem C et al., 2016, Impact of Pharmacogenetic Markers of CYP2D6 and DRD2 on Prolactin Response in Risperidone-Treated Thai Children and Adolescents With Autism Spectrum Disorders., J Clin Psychopharmacol
Blasi G et al., 2015, Variation in Dopamine D2 and Serotonin 5-HT2A Receptor Genes is Associated with Working Memory Processing and Response to Treatment with Antipsychotics., Neuropsychopharmacology
López-Rodríguez R et al., 2013, Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers., Pharmacogenomics
Roke Y et al., 2013, The effect of the Taq1A variant in the dopamine D₂ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys., Pharmacogenet Genomics
Houston JP et al., 2012, Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia., J Clin Psychiatry
Houston J et al., 2011, Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women., Psychiatry Res
Müller DJ et al., 2012, Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain., Pharmacogenomics J
Hong CJ et al., 2010, Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment., Pharmacogenet Genomics
Zhang JP et al., 2010, D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis., Am J Psychiatry
Yasui-Furukori N et al., 2008, Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients., Prog Neuropsychopharmacol Biol Psychiatry
Bakker PR et al., 2008, Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions., Mol Psychiatry
Alenius M et al., 2008, Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting., J Psychiatr Res
Zai CC et al., 2007, Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients., Mol Psychiatry
Suzuki A et al., 2001, The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients., Pharmacogenetics
Batra S, 1976, Unconjugated estradiol in the myometrium of pregnancy., Endocrinology
Ohara K et al., 1998, Functional polymorphism of -141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia., Psychiatry Res
Li T et al., 1998, Case-control, haplotype relative risk and transmission disequilibrium analysis of a dopamine D2 receptor functional promoter polymorphism in schizophrenia., Schizophr Res
Shen YC et al., 2009, Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients., J Psychiatr Res
Xing Q et al., 2007, The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients., Int J Neuropsychopharmacol
Lencz et al., 2006, DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients., Am J Psychiatry
Lerman C et al., 2006, Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials., Neuropsychopharmacology
Hwang R et al., 2005, Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations., Psychopharmacology (Berl)
Wu et al., 2005, Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients., Neurosci. Lett.
Yamanouchi Y et al., 2003, Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone., Pharmacogenomics J
Li T et al., 2002, Allelic association analysis of the dopamine D2, D3, 5-HT2A, and GABA(A)gamma2 receptors and serotonin transporter genes with heroin abuse in Chinese subjects., Am J Med Genet
Thacker et al., 2006, The effects of adulthood olanzapine treatment on cognitive performance and neurotrophic factor content in male and female rats neonatally treated with quinpirole., Eur. J. Neurosci.
Weizman et al., 2003, The antinociceptive effect of amisulpride in mice is mediated through opioid mechanisms., Eur. J. Pharmacol.
Naiker et al., 2006, Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat., Eur. J. Pharmacol.
Uchida et al., 2007, Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine., Life Sci.
Jordan et al., 2007, In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling., J. Psychopharmacol. (Oxford)
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry
Brafford MV et al., 2014, Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting., J Adv Pract Oncol
Tiwari AK et al., 2010, Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients., Prog Neuropsychopharmacol Biol Psychiatry
Bymaster et al., 1999, Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro., Schizophr. Res.
Ono S et al., 2015, GIPR Gene Polymorphism and Weight Gain in Patients With Schizophrenia Treated With Olanzapine., J Neuropsychiatry Clin Neurosci
Ono S et al., 2012, Association between the GIPR gene and the insulin level after glucose loading in schizophrenia patients treated with olanzapine., Pharmacogenomics J
Kao AC et al., 2014, Methylenetetrahydrofolate reductase gene variants and antipsychotic-induced weight gain and metabolic disturbances., J Psychiatr Res
Söderberg MM et al., 2013, Influence of CYP1A1/CYP1A2 and AHR polymorphisms on systemic olanzapine exposure., Pharmacogenet Genomics
Shahid et al., 2009, Asenapine: a novel psychopharmacologic agent with a unique human receptor signature., J. Psychopharmacol. (Oxford)
Fernández et al., 2005, Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents., J. Med. Chem.
Crisafulli C et al., 2012, Case-control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics., Eur Arch Psychiatry Clin Neurosci
Hutchison et al., 2006, The effect of olanzapine on craving and alcohol consumption., Neuropsychopharmacology
Adams DH et al., 2008, Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder., Hum Psychopharmacol
Porcelli S et al., 2016, PDE7B, NMBR and EPM2A Variants and Schizophrenia: A Case-Control and Pharmacogenetics Study., Neuropsychobiology
Chagnon YC et al., 2007, Possible association of the pro-melanin-concentrating hormone gene with a greater body mass index as a side effect of the antipsychotic olanzapine., Am J Med Genet B Neuropsychiatr Genet
Delacrétaz A et al., 2017, Association of variants in SH2B1 and RABEP1 with worsening of low-density lipoprotein and glucose parameters in patients treated with psychotropic drugs., Gene
Altschuler et al., 2005, Using histamine (H1) antagonists, in particular atypical antipsychotics, to treat anemia of chronic disease via interleukin-6 suppression., Med. Hypotheses
Poyurovsky et al., 2005, The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients., Int Clin Psychopharmacol
Rasmussen et al., 2005, Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine., J. Pharmacol. Exp. Ther.
Cabaleiro T et al., 2013, Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects., Hum Psychopharmacol
Nikolac Perkovic M et al., 2014, Association between the brain-derived neurotrophic factor Val66Met polymorphism and therapeutic response to olanzapine in schizophrenia patients., Psychopharmacology (Berl)
Zhang JP et al., 2016, Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis., Schizophr Bull
Czerwensky F et al., 2013, MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain?, Int J Neuropsychopharmacol
Nurmi EL et al., 2013, Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies., Transl Psychiatry
Malhotra AK et al., 2012, Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain., Arch Gen Psychiatry
Chowdhury NI et al., 2013, Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene., Pharmacogenomics J
Bymaster et al., 1996, Radioreceptor binding profile of the atypical antipsychotic olanzapine., Neuropsychopharmacology
Maffioletti E et al., 2020, Association study between HTR2A rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients., Drug Dev Res
Salloum NC et al., 2014, Towards the clinical implementation of pharmacogenetics in bipolar disorder., BMC Med
Laika B et al., 2010, Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome., Pharmacogenomics J
Angelucci F et al., 2009, Delusion symptoms and response to antipsychotic treatment are associated with the 5-HT2A receptor polymorphism (102T/C) in Alzheimer's disease: a 3-year follow-up longitudinal study., J Alzheimers Dis
Ujike H et al., 2008, Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study., J Clin Psychiatry
Thomas P et al., 2008, Correlates of response to Olanzapine in a North Indian Schizophrenia sample., Psychiatry Res
Moresco et al., 2004, Cerebral D2 and 5-HT2 receptor occupancy in Schizophrenic patients treated with olanzapine or clozapine., J. Psychopharmacol. (Oxford)
Yatham et al., 2005, Atypical antipsychotics in bipolar depression: potential mechanisms of action., J Clin Psychiatry
McDonald et al., 2003, Enhancement of latent inhibition by two 5-HT2A receptor antagonists only when given at both pre-exposure and conditioning., Psychopharmacology (Berl.)
Padín et al., 2006, Parallel regulation by olanzapine of the patterns of expression of 5-HT2A and D3 receptors in rat central nervous system and blood cells., Neuropharmacology
Sharpley et al., 2005, Olanzapine increases slow wave sleep and sleep continuity in SSRI-resistant depressed patients., J Clin Psychiatry
Söderberg MM et al., 2013, Influence of FMO1 and 3 polymorphisms on serum olanzapine and its N-oxide metabolite in psychiatric patients., Pharmacogenomics J
Drago A et al., 2014, Genome-wide association study supports the role of the immunological system and of the neurodevelopmental processes in response to haloperidol treatment., Pharmacogenet Genomics
Theisen et al., 2007, No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation., Pharmacogenomics J.
Wood et al., 2006, Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade., CNS Neurol Disord Drug Targets
Overstreet et al., 2007, Drug challenges reveal differences in mediation of stress facilitation of voluntary alcohol drinking and withdrawal-induced anxiety in alcohol-preferring P rats., Alcohol. Clin. Exp. Res.
Zhang et al., 2006, Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms., Biochem. Pharmacol.
Hertel, 2006, Comparing sertindole to other new generation antipsychotics on preferential dopamine output in limbic versus striatal projection regions: mechanism of action., Synapse
Ma X et al., 2014, HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis., Int J Psychiatry Clin Pract
Mulder H et al., 2009, HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study., J Clin Psychopharmacol
De Luca V et al., 2007, HTR2C haplotypes and antipsychotics-induced weight gain: X-linked multimarker analysis., Hum Psychopharmacol
Sicard MN et al., 2010, Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis., Pharmacogenomics
Mulder H et al., 2007, The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia., J Clin Psychopharmacol
Correia CT et al., 2010, Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions., Pharmacogenomics J
Risselada AJ et al., 2012, Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study., Pharmacogenomics J
Opgen-Rhein C et al., 2010, Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample., Pharmacogenomics
Dos Santos-Júnior A et al., 2016, Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents., Int J Endocrinol
Godlewska BR et al., 2009, Olanzapine-induced weight gain is associated with the -759C/T and -697G/C polymorphisms of the HTR2C gene., Pharmacogenomics J
Mulder H et al., 2007, The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study., Pharmacogenomics J
McClay JL et al., 2011, Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia., Neuropsychopharmacology
Mancama D et al., 2007, Choline acetyltransferase variants and their influence in schizophrenia and olanzapine response., Am J Med Genet B Neuropsychiatr Genet
Söderberg MM et al., 2014, No influence of CYP3A43 rs472660G> A on steady-state serum olanzapine concentrations in white psychiatric patients., Pharmacogenet Genomics
Bigos KL et al., 2011, Genetic variation in CYP3A43 explains racial difference in olanzapine clearance., Mol Psychiatry
Brandl EJ et al., 2014, Genetic variation in the GCG and in the GLP1R genes and antipsychotic-induced weight gain., Pharmacogenomics
Herken H et al., 2009, The association of olanzapine-induced weight gain with peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism in patients with schizophrenia., DNA Cell Biol
Vázquez-Bourgon J et al., 2010, Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis., Psychiatry Res
Monteleone P et al., 2010, Endocannabinoid Pro129Thr FAAH functional polymorphism but not 1359G/A CNR1 polymorphism is associated with antipsychotic-induced weight gain., J Clin Psychopharmacol
Tiwari AK et al., 2010, A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia., Neuropsychopharmacology
Brandl EJ et al., 2013, Exploratory study on association of genetic variation in TBC1D1 with antipsychotic-induced weight gain., Hum Psychopharmacol
Wang R et al., 2018, ABCB1 1199G > A Polymorphism Impacts Transport Ability of P-gp-Mediated Antipsychotics., DNA Cell Biol
Lin YC et al., 2006, The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia., Ther Drug Monit
Srivastava V et al., 2008, Genetic correlates of olanzapine-induced weight gain in schizophrenia subjects from north India: role of metabolic pathway genes., Pharmacogenomics

OLANZAPINE PMCH

Interaction Score: 1.62

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17541984

Sources:
PharmGKB
OLANZAPINE GIPR

Interaction Score: 1.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25321336 21747410

Sources:
PharmGKB
OLANZAPINE TBC1D1

Interaction Score: 0.81

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23364847

Sources:
PharmGKB
OLANZAPINE SV2C

Interaction Score: 0.81

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
OLANZAPINE GSTM3

Interaction Score: 0.81

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23559402

Sources:
PharmGKB
OLANZAPINE SPOPL

Interaction Score: 0.81

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
OLANZAPINE ANKK1

Interaction Score: 0.62

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26872113 23859574 23851570 23559402 20714340 18579277 18180754 18086475 17767146

Sources:
PharmGKB
OLANZAPINE FMO1

Interaction Score: 0.54

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23147717

Sources:
PharmGKB
OLANZAPINE CYP3A43

Interaction Score: 0.35

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24595013 21519338

Sources:
PharmGKB
OLANZAPINE IL1A

Interaction Score: 0.27

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21107309

Sources:
PharmGKB
OLANZAPINE MC4R

Interaction Score: 0.27

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27217270 23920449 23799528 22566560 22310352

Sources:
PharmGKB
OLANZAPINE EIF2AK4

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24751813

Sources:
PharmGKB
OLANZAPINE EPM2A

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27092952

Sources:
PharmGKB
OLANZAPINE FMO3

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23147717

Sources:
PharmGKB
OLANZAPINE RABEP1

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28694205

Sources:
PharmGKB
OLANZAPINE SH2B1

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28694205

Sources:
PharmGKB
OLANZAPINE HTR2C

Interaction Score: 0.18

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Specific Action of the Ligand Inverse agonist

Endogenous Drug? False

Direct Interaction? True

PMIDs:
16983399 16918396 17624999 10227113 11752352 16336943 16952163 22967772 25152019 19142101 17702092 21121776 19193342 17632216 19997080 20680028 20504252 26880915 27217270 19434072 17016522 25032030

Sources:
DrugBank TdgClinicalTrial ChemblInteractions TEND GuideToPharmacology PharmGKB
OLANZAPINE DRD2

Interaction Score: 0.16

Interaction Types & Directionality:

antagonist (inhibitory)

agonist (activating)

Interaction Info:

Mechanism of Interaction D2-like dopamine receptor antagonist

Direct Interaction yes

Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv

PMIDs:
9918131 28673279 26872113 25563748 23859574 23851570 22967772 21095016 20714340 20375926 20194480 18579277 18180754 18086475 17767146 11505224 991813 9858029 9713903 18926547 17105675 16513877 16123753 15830237 15694263 14610521 11920858 17067304 14575800 16730699 17316700 17092971 11752352 17848919 25032030

Sources:
DrugBank TdgClinicalTrial ChemblInteractions TEND GuideToPharmacology PharmGKB TTD
OLANZAPINE TPMT

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23559402

Sources:
PharmGKB
OLANZAPINE CHAT

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17503482

Sources:
PharmGKB
OLANZAPINE ATP1A2

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
OLANZAPINE GNB3

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19193342

Sources:
PharmGKB
OLANZAPINE DRD5

Interaction Score: 0.11

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv

Novel drug target Established target

Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

PMIDs:
17848919 10227113 25032030

Sources:
DrugBank TdgClinicalTrial
OLANZAPINE LEP

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18681781

Sources:
PharmGKB
OLANZAPINE GCG

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24624910

Sources:
PharmGKB
OLANZAPINE HTR2A

Interaction Score: 0.09

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv

Novel drug target Established target

Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

PMIDs:
32462699 24885933 19636338 19494443 19193342 19000940 15358979 16038601 17316700 10227113 14530903 16905159 15816787 11752352 17848919 25032030

Sources:
DrugBank TdgClinicalTrial ChemblInteractions TEND GuideToPharmacology PharmGKB
OLANZAPINE HTR6

Interaction Score: 0.08

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name ALKS 3831

Trial Name OREX-003, olanzapine plus zonisamide SR

Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

PMIDs:
17848919 25032030

Sources:
DrugBank TdgClinicalTrial GuideToPharmacology
OLANZAPINE DRD4

Interaction Score: 0.08

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction D2-like dopamine receptor antagonist

Direct Interaction yes

Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv

PMIDs:
16237394 11752352 25032030

Sources:
DrugBank TdgClinicalTrial ChemblInteractions TEND
OLANZAPINE CCKBR

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20732371

Sources:
PharmGKB
OLANZAPINE CNR1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23799528 20631561 20107430

Sources:
PharmGKB
OLANZAPINE DRD3

Interaction Score: 0.07

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction D2-like dopamine receptor antagonist

Direct Interaction yes

Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv

PMIDs:
17848919 11752352 18320559 25032030

Sources:
DrugBank TdgClinicalTrial ChemblInteractions TEND PharmGKB
OLANZAPINE FAAH

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20631561

Sources:
PharmGKB
OLANZAPINE HTR1E

Interaction Score: 0.07

Interaction Types & Directionality:

antagonist (inhibitory)

agonist (activating)

Interaction Info:

Trial Name ALKS 3831

Trial Name OREX-003, olanzapine plus zonisamide SR

Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

PMIDs:
17848919

Sources:
TdgClinicalTrial GuideToPharmacology
OLANZAPINE CYP1A1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23492908

Sources:
PharmGKB
OLANZAPINE MTHFR

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24725652

Sources:
PharmGKB
OLANZAPINE CHRM4

Interaction Score: 0.06

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv

Novel drug target Established target

Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

PMIDs:
17848919 10227113 25032030

Sources:
DrugBank TdgClinicalTrial TEND
OLANZAPINE HTR3A

Interaction Score: 0.05

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv

Novel drug target Established target

Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

PMIDs:
17848919 25032030

Sources:
DrugBank TdgClinicalTrial
OLANZAPINE ADRA1B

Interaction Score: 0.05

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name ALKS 3831

Trial Name OREX-003, olanzapine plus zonisamide SR

Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

PMIDs:
10227113 17848919 17316700 11752352

Sources:
DrugBank TdgClinicalTrial TEND
OLANZAPINE HRH1

Interaction Score: 0.05

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Specific Action of the Ligand Antagonist

Endogenous Drug? False

Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv

PMIDs:
15893120 15729086 17316700 10227113 11752352 16141369 25032030

Sources:
DrugBank TdgClinicalTrial TEND GuideToPharmacology
OLANZAPINE UGT1A1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23559402

Sources:
PharmGKB
OLANZAPINE CHRM2

Interaction Score: 0.04

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name ALKS 3831

Trial Name OREX-003, olanzapine plus zonisamide SR

Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

PMIDs:
17848919 10227113 25032030

Sources:
DrugBank TdgClinicalTrial TEND
OLANZAPINE DRD1

Interaction Score: 0.04

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name ALKS 3831

Trial Name OREX-003, olanzapine plus zonisamide SR

Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

PMIDs:
18308814 15771415 10227113 17848919 11752352 25032030

Sources:
DrugBank TdgClinicalTrial TEND
OLANZAPINE CHRM5

Interaction Score: 0.04

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv

Novel drug target Established target

Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

PMIDs:
17848919 10227113

Sources:
TdgClinicalTrial TEND
OLANZAPINE HTR1A

Interaction Score: 0.04

Interaction Types & Directionality:

agonist (activating)

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name ALKS 3831

Trial Name OREX-003, olanzapine plus zonisamide SR

Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

PMIDs:
22120873 17848919 25032030

Sources:
DrugBank TdgClinicalTrial GuideToPharmacology PharmGKB
OLANZAPINE HTR7

Interaction Score: 0.04

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name ALKS 3831

Trial Name OREX-003, olanzapine plus zonisamide SR

Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

PMIDs:
17848919

Sources:
TdgClinicalTrial GuideToPharmacology
OLANZAPINE CHRM1

Interaction Score: 0.04

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv

Novel drug target Established target

Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

PMIDs:
17848919 17316700 10227113 25032030

Sources:
DrugBank TdgClinicalTrial TEND
OLANZAPINE HTR1D

Interaction Score: 0.04

Interaction Types & Directionality:

antagonist (inhibitory)

agonist (activating)

Interaction Info:

Trial Name ALKS 3831

Novel drug target Established target

Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv

PMIDs:
17848919

Sources:
TdgClinicalTrial GuideToPharmacology
OLANZAPINE CHRM3

Interaction Score: 0.04

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv

Novel drug target Established target

Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

PMIDs:
17848919 10227113 25032030

Sources:
DrugBank TdgClinicalTrial TEND
OLANZAPINE HTR1B

Interaction Score: 0.03

Interaction Types & Directionality:

antagonist (inhibitory)

agonist (activating)

Interaction Info:

Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv

Novel drug target Established target

Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

PMIDs:
17848919

Sources:
TdgClinicalTrial GuideToPharmacology
OLANZAPINE ADRB3

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19193342

Sources:
PharmGKB
OLANZAPINE SLC6A4

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23859574 20031235

Sources:
PharmGKB
OLANZAPINE HTR1F

Interaction Score: 0.03

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Specific Action of the Ligand Full agonist

Endogenous Drug? False

PMIDs:
None found

Sources:
GuideToPharmacology
OLANZAPINE BDNF

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24595507

Sources:
PharmGKB
OLANZAPINE ADRA1A

Interaction Score: 0.02

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name ALKS 3831

Trial Name OREX-003, olanzapine plus zonisamide SR

Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

PMIDs:
17848919 10227113 25032030

Sources:
DrugBank TdgClinicalTrial
OLANZAPINE AHR

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23492908

Sources:
PharmGKB
OLANZAPINE COMT

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
OLANZAPINE GABRA1

Interaction Score: 0.02

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
8822531 25032030

Sources:
DrugBank
OLANZAPINE GFER

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
OLANZAPINE ADRA2B

Interaction Score: 0.02

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name ALKS 3831

Trial Name OREX-003, olanzapine plus zonisamide SR

Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

PMIDs:
17848919

Sources:
TdgClinicalTrial
OLANZAPINE CYP3A5

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23559402

Sources:
PharmGKB
OLANZAPINE ADRA2C

Interaction Score: 0.02

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv

Novel drug target Established target

Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

PMIDs:
17848919

Sources:
TdgClinicalTrial
OLANZAPINE ADRB1

Interaction Score: 0.01

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
8822531

Sources:
DrugBank
OLANZAPINE ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29443543 18086475 17038883

Sources:
PharmGKB
OLANZAPINE ADRA2A

Interaction Score: 0.01

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv

Novel drug target Established target

Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

PMIDs:
17848919

Sources:
TdgClinicalTrial
OLANZAPINE GAA

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
OLANZAPINE GLP1R

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24624910

Sources:
PharmGKB
OLANZAPINE PPARG

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19622037

Sources:
PharmGKB
OLANZAPINE RGS4

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
OLANZAPINE CYP2C9

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23559402

Sources:
PharmGKB
OLANZAPINE CYP3A4

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23559402

Sources:
PharmGKB

DrugBank: DB00334

Version: 5.1.7

Alternate Names:

OLANZAPINE DrugBank Drug Name

132539-06-1 CAS Number

Abbott-olanzapine ODT Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Publications:

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

Moresco et al., 2004, Cerebral D2 and 5-HT2 receptor occupancy in Schizophrenic patients treated with olanzapine or clozapine., J. Psychopharmacol. (Oxford)

Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.

TEND: OLANZAPINE
- Version: 01-August-2011
Alternate Names:

OLANZAPINE Primary Drug Name

Drug Info:

Drug Class antipsychotic agents

Year of Approval 1996

Publications:
TdgClinicalTrial: OLANZAPINE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antipsychotic agent

Drug Class Small Molecule

FDA Approval approved

Publications:

PharmGKB: olanzapine

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Tiwari AK et al., 2010, Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients., Prog Neuropsychopharmacol Biol Psychiatry

Ono S et al., 2012, Association between the GIPR gene and the insulin level after glucose loading in schizophrenia patients treated with olanzapine., Pharmacogenomics J

Ono S et al., 2015, GIPR Gene Polymorphism and Weight Gain in Patients With Schizophrenia Treated With Olanzapine., J Neuropsychiatry Clin Neurosci

TTD: Olanzapine
- Version: 2020.06.01
Alternate Names:

D0V4QS TTD Drug ID

Drug Info:

Publications:
DTC: OLANZAPINE
- Version: 02-September-2020
Alternate Names:

CHEMBL715 ChEMBL Drug ID

Drug Info:

Publications:
GuideToPharmacology: 135650756
- Version: 29-September-2020
Alternate Names:

OLANZAPINE GuideToPharmacology Ligand Name

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL715
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL715
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Specific Action of the Ligand	Inverse agonist
Endogenous Drug?	False
Direct Interaction?	True

Mechanism of Interaction	D2-like dopamine receptor antagonist
Direct Interaction	yes
Trial Name	olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv

Trial Name	olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv
Novel drug target	Established target
Trial Name	Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

Trial Name	ALKS 3831
Trial Name	OREX-003, olanzapine plus zonisamide SR
Trial Name	Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

Specific Action of the Ligand	Antagonist
Endogenous Drug?	False
Trial Name	olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv

Specific Action of the Ligand	Full agonist
Endogenous Drug?	False

OLANZAPINE	DrugBank Drug Name
132539-06-1	CAS Number
Abbott-olanzapine ODT	Drug Brand

Drug Type	small molecule
Drug Groups	approved
Drug Groups	investigational

antagonist (inhibitory)
agonist (activating)

OLANZAPINE Drug Record

OLANZAPINE chembl:CHEMBL715 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17541984

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25321336 21747410

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23364847

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23559402

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26872113 23859574 23851570 23559402 20714340 18579277 18180754 18086475 17767146

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23147717

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24595013 21519338

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21107309

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27217270 23920449 23799528 22566560 22310352

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24751813

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27092952

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23147717

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28694205

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28694205

Sources: PharmGKB

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Specific Action of the Ligand Inverse agonist Endogenous Drug? False Direct Interaction? True

PMIDs: 16983399 16918396 17624999 10227113 11752352 16336943 16952163 22967772 25152019 19142101 17702092 21121776 19193342 17632216 19997080 20680028 20504252 26880915 27217270 19434072 17016522 25032030

Sources: DrugBank TdgClinicalTrial ChemblInteractions TEND GuideToPharmacology PharmGKB

Interaction Types & Directionality: antagonist (inhibitory) agonist (activating)

Interaction Info: Mechanism of Interaction D2-like dopamine receptor antagonist Direct Interaction yes Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv

Sources: DrugBank TdgClinicalTrial ChemblInteractions TEND GuideToPharmacology PharmGKB TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23559402

Sources: PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17541984

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25321336 21747410

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23364847

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23559402

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26872113 23859574 23851570 23559402 20714340 18579277 18180754 18086475 17767146

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23147717

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24595013 21519338

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
21107309

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27217270 23920449 23799528 22566560 22310352

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24751813

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27092952

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23147717

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28694205

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28694205

Sources:
PharmGKB

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Specific Action of the Ligand Inverse agonist

Endogenous Drug? False

Direct Interaction? True

PMIDs:
16983399 16918396 17624999 10227113 11752352 16336943 16952163 22967772 25152019 19142101 17702092 21121776 19193342 17632216 19997080 20680028 20504252 26880915 27217270 19434072 17016522 25032030

Sources:
DrugBank TdgClinicalTrial ChemblInteractions TEND GuideToPharmacology PharmGKB

Interaction Types & Directionality:

antagonist (inhibitory)

agonist (activating)

Interaction Info:

Mechanism of Interaction D2-like dopamine receptor antagonist

Direct Interaction yes

Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv

Sources:
DrugBank TdgClinicalTrial ChemblInteractions TEND GuideToPharmacology PharmGKB TTD

Interaction Types & Directionality:

n/a

PMIDs:
23559402

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17503482

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
19193342

Sources:
PharmGKB

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv

Novel drug target Established target

Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

PMIDs:
17848919 10227113 25032030

Sources:
DrugBank TdgClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
18681781

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24624910

Sources:
PharmGKB

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv

Novel drug target Established target

Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

PMIDs:
32462699 24885933 19636338 19494443 19193342 19000940 15358979 16038601 17316700 10227113 14530903 16905159 15816787 11752352 17848919 25032030